Proteomic biomarkers for autoimmune disease PROTEOMICS Hueber, W., Robinson, W. H. 2006; 6 (14): 4100-4105


Autoimmune diseases affect 3% of the world population, yet the diagnosis and classification of autoimmune diseases remain based on clinical examination combined with traditional laboratory tests and imaging studies. The development of genomic and proteomic technologies provides an unprecedented ability to identify novel biosignatures to diagnose, classify, and guide therapeutic decision making in patients with autoimmune disease. In this article, we review recent advances in proteomics technologies and their application to autoimmune disease.

View details for DOI 10.1002/pmic.200600017

View details for PubMedID 16786488